Azenta Strategy and Business Model

Executive Overview

Azenta is a Burlington, Massachusetts-based life sciences tools and services company focused on one narrow but important problem: helping customers store, move, track, and analyze biological and chemical samples with high reliability. The company traces its roots to 1978 as Brooks Automation, but its current shape reflects a major portfolio shift: after selling its semiconductor automation business in 2022, it rebranded as Azenta and became a pure-play life sciences company. As of fiscal 2024, Azenta reported revenue of #N/A.

Azenta operates through two reported segments: Sample Management Solutions and Multiomics. Sample Management Solutions includes biostorage, outsourced repository services, cold-chain logistics, laboratory consumables, automation, and informatics. Multiomics includes sequencing and related genomic services, including work performed under the GENEWIZ brand. Its customers are primarily biopharma, biotech, academic, government, and other research organizations that care deeply about sample integrity, chain of custody, compliance, and turnaround time. Strategically, Azenta is trying to pair a stickier infrastructure-style sample management business with analytical lab services, while improving the profitability and focus of its Multiomics operations and using its balance sheet selectively for capability-building acquisitions.

Azenta at a Glance

Logo
Common name	Azenta
Full legal name	Azenta, Inc.
Headquarters	Burlington, Massachusetts, United States
Ownership	Public company
Ticker	AZTA
Exchange	NASDAQ
Market Cap	$1.03B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1978 as Brooks Automation; built a life sciences platform through acquisitions during the 2010s; sold the legacy semiconductor automation business in 2022; rebranded as Azenta in 2022.
Industry or industries	Life sciences tools and services; sample management; biostorage; cold-chain logistics; genomics and multiomics services
Key products or services	Sample storage and repository services, automated storage systems, temperature-controlled logistics, sample consumables, sample informatics, sequencing and genomic services
Geographic footprint	Global, with operations and customers across North America, Europe, and Asia-Pacific
Business segments as officially reported	Sample Management Solutions; Multiomics
Company website	https://www.azenta.com/

1. What Is the Strategy of Azenta?

Since becoming a pure-play life sciences company in 2022, Azenta has framed its strategy around being a specialized partner across the sample lifecycle: collecting, storing, tracking, moving, and analyzing samples for research and therapeutic development. Using the Playing to Win lens, the strategy is clearer than it first appears. Azenta is not trying to be a general life sciences conglomerate. It is trying to win in workflows where sample integrity, traceability, and operational reliability matter enough that customers will pay for a trusted platform.

1a. What is the winning aspiration of Azenta?

Azenta’s winning aspiration is to become a trusted infrastructure and services partner for life sciences customers handling valuable or sensitive samples. In practical terms, winning means being embedded in customer workflows from sample accessioning and storage through retrieval, transport, and omics analysis. Public communications since the 2022 portfolio transformation point to a goal of building a more focused, growth-oriented life sciences company with stronger recurring revenue characteristics and better long-term profitability than its former mixed portfolio allowed.
1b. Where does Azenta play?

Azenta plays in two adjacent fields: outsourced sample management and multiomics services. Its target customers are biopharma, biotech, academic, government, and other research organizations, especially those handling regulated, irreplaceable, or temperature-sensitive materials. Geographically, it competes globally, with a meaningful presence in North America, Europe, and Asia. Product-wise, it chooses workflows where sample handling complexity is high enough to reward infrastructure, automation, and quality systems rather than commodity pricing alone.
1c. How does Azenta plan to win?

Azenta appears to plan to win through workflow breadth and execution quality rather than through lowest price. The differentiators are the ability to combine sample storage, repository services, cold-chain logistics, consumables, automation, informatics, and omics analysis; the operational discipline needed to preserve sample integrity; and the switching costs created when customers entrust critical collections to a third party. In Multiomics, where pricing is more competitive, Azenta’s better route is not to be the cheapest sequencing provider, but to pair lab services with convenience, digital ordering, turnaround time, and existing relationships from sample management.
1d. What capabilities must Azenta have in place?

To execute this strategy, Azenta needs several capabilities that reinforce each other: temperature-controlled storage infrastructure; automation engineering; laboratory operations; bioinformatics and data handling; quality and compliance systems; logistics coordination; and enterprise account management. It also needs acquisition integration capabilities, because the current portfolio has been built partly through M&A, and selective tuck-ins remain strategically plausible.
1e. What management systems does Azenta require?

Azenta’s strategy requires management systems built around quality, utilization, and customer retention. That means tight monitoring of sample integrity, turnaround time, repository capacity, lab throughput, error rates, and customer service levels. It also requires capital-allocation discipline: deciding where to expand storage capacity, where to optimize lab footprints, and how to balance organic investment, acquisitions, and shareholder returns. Because Azenta runs two businesses with different economics, management also needs clear segment-level operating metrics rather than relying only on consolidated revenue growth.

2. What Are the Current Strategic Initiatives of Azenta?

Azenta’s public materials in fiscal 2024 and around that period pointed to a set of practical priorities rather than a dramatic reinvention. The company’s main initiatives can be summarized as follows:

Expand the higher-value Sample Management Solutions platform. Azenta continues to emphasize outsourced sample repository services, biostorage, cold-chain logistics, automation-compatible consumables, and informatics. These activities tend to be more embedded in customer workflows and can produce more recurring or repeatable revenue than one-off equipment sales.
Improve the operating model of Multiomics. Public commentary has highlighted the need to improve growth quality and profitability in Multiomics through productivity improvement, cost discipline, commercial focus, and better mix. This matters because the omics market can be more competitive and volume-sensitive than repository services.
Cross-sell across the sample lifecycle. A recurring strategic theme is that Azenta can serve the same customer with storage, transport, consumables, and analytical services. The logic is straightforward: once Azenta already handles a customer’s samples, it is well positioned to win adjacent laboratory work.
Invest in automation, informatics, and digital interfaces. Azenta’s value proposition depends heavily on traceability and workflow efficiency. That makes customer portals, laboratory information systems, sample tracking, and automation a continuing strategic priority rather than back-office plumbing.
Pursue disciplined portfolio shaping. The 2022 sale of the semiconductor automation business created both focus and financial flexibility. Since then, Azenta has had the capacity to pursue selective tuck-in acquisitions and capability expansion in life sciences while avoiding a return to unrelated diversification.
Target resilient end markets within life sciences. Azenta’s positioning is strongest in biopharma, biotech, and other customers whose programs require strict sample integrity and documented handling. Areas such as biologics and cell and gene therapy are especially relevant because cold-chain reliability and chain of custody matter more there.

3. What Is the Business Model of Azenta?

What customers actually buy

Customers buy a mix of infrastructure-like services and laboratory work. In Sample Management Solutions, they buy sample storage, repository operations, retrieval, kitting, transport, consumables, and automation-backed workflow support. In Multiomics, they buy sequencing and related omics services on a per-order or program basis.

What portion of the model appears recurring or repeat-driven versus one-time

The business is mixed. Repository storage, sample management, and some logistics relationships are the most recurring because customers often keep collections in long-term storage and repeatedly request retrievals, audits, aliquoting, or transport. Multiomics revenue is less contractual in form, but much of it can still be repeat-driven when researchers place recurring orders through digital portals. Equipment and some consumables are more transactional and can be tied to customer project cycles.

How pricing power works

Pricing power is stronger in outsourced storage and sample management than in commoditized lab services. When a customer has validated Azenta into a regulated or mission-critical workflow, switching becomes cumbersome and risky. That supports pricing through service value, compliance, and reliability. By contrast, sequencing and related analytical services usually face more visible price competition and require differentiation through quality, turnaround time, and ease of use.

Why the business mix matters

The mix matters because Azenta’s segments do not have identical economics. Sample Management Solutions appears structurally stickier and more differentiated, while Multiomics can offer faster volume growth and broader customer touchpoints but may be more exposed to demand swings, pricing pressure, and lab utilization issues. A healthier mix toward recurring sample services can make the total company more resilient.

What drives gross margin, operating margin, and cash generation

Gross margin depends on utilization of repositories and labs, service mix, automation, and input costs such as reagents, freight, packaging, and labor. Operating margin also depends on commercial efficiency and corporate-cost leverage. Cash generation improves when Azenta grows recurring service revenue and keeps working capital under control, but storage infrastructure, laboratory capacity, and automation systems still require capital investment.

Revenue model

Azenta’s revenue model is best described as a hybrid of service fees, per-sample or per-order laboratory charges, recurring storage fees, and product sales. It is not a subscription company in the software sense, but parts of the sample management business have subscription-like retention characteristics.

4. What Products and/or Services Does Azenta Sell?

Azenta sells products and services across two main categories.

Sample Management Solutions

Biostorage and repository services: outsourced storage of biological and chemical samples across ambient, refrigerated, frozen, and cryogenic conditions, with inventory control and chain-of-custody support.
Sample handling and workflow services: accessioning, retrieval, picking, aliquoting, sorting, and related operational services around customer collections.
Cold-chain and temperature-controlled logistics: movement of sensitive materials where temperature maintenance and documentation matter.
Consumables and labware: sample tubes, plates, and other storage-related consumables designed to work within automated workflows.
Automation and informatics: systems and software that help customers track, access, and manage samples.

Multiomics

Sanger sequencing and next-generation sequencing: core genomic analysis services for research and development workflows.
Gene synthesis and related molecular biology services: offerings that support research design, construct development, and laboratory workflows.
Other omics and analytical services: broader research support capabilities delivered through laboratory operations and data workflows.

What appears most important strategically

Sample Management Solutions appears to be the more differentiated and durable core of Azenta’s portfolio because it sits closer to infrastructure, quality systems, and long-term customer workflows. Multiomics is strategically important because it expands Azenta’s wallet share and daily relevance to researchers, but it appears more operationally sensitive and more exposed to competition. In that sense, Sample Management Solutions looks like the stabilizer, while Multiomics is the broader reach engine if executed well.

5. What Are the Key Competitors or Peers of Azenta?

Azenta does not have a single perfect like-for-like competitor because its portfolio spans sample management, storage, logistics, and omics services. Its competitive set varies by product line.

Thermo Fisher Scientific: a broad life sciences tools company with overlap in sample handling, storage-related equipment, genomics workflows, and outsourced laboratory support.
Eurofins Scientific: a major global laboratory services company with meaningful overlap in outsourced genomics and analytical services.
Cryoport: a close adjacent competitor in temperature-controlled logistics and biostorage, particularly in cell and gene therapy workflows.
Hamilton Company: a well-known competitor in laboratory automation, including sample management and workflow equipment.
Tecan Group: a major lab automation and instrument company that overlaps in workflow automation and sample-processing environments.
SPT Labtech: a specialist in sample management and laboratory automation, particularly in high-throughput research settings.
BGI Genomics: a large-scale omics and sequencing competitor, especially relevant in global genomic services.
Twist Bioscience: a closer peer in gene-related research support offerings, particularly where gene synthesis and synthetic biology workflows overlap.
PHCbi: a notable competitor in ultra-low-temperature and biobank storage equipment rather than end-to-end outsourced services.

The key strategic point is that Azenta competes against different specialists in different parts of its portfolio. That can be a disadvantage in very focused categories, but it also lets Azenta offer a broader workflow solution than single-point competitors can.

6. What Is the Marketing Strategy of Azenta?

Azenta’s marketing approach is business-to-business, technical, and workflow-oriented. This is not a consumer brand story. Customers evaluate Azenta on quality, compliance, turnaround time, sample integrity, and operational reliability, so marketing serves mainly to demonstrate credibility and reduce perceived execution risk.

Several forms of marketing appear especially relevant:

Scientific and technical marketing: webinars, application content, protocol support, and conference presence help Azenta reach researchers and laboratory decision makers.
Account-based marketing: large biopharma and biotech customers often require tailored engagement because buying decisions involve procurement, scientists, operations teams, and quality personnel.
Digital demand capture: the Multiomics business, especially through GENEWIZ, benefits from online ordering, digital account management, and repeat-use workflows that can improve customer convenience.
Brand trust marketing: in sample management, messaging around chain of custody, sample preservation, quality systems, and global service capability likely matters more than broad brand advertising.

Marketing appears to be a supporting capability rather than Azenta’s main differentiator. The real differentiator is operational performance. Marketing’s role is to make those capabilities legible to buyers.

7. What Are the Key Customer Segments of Azenta?

Azenta serves a research- and healthcare-oriented customer base rather than end consumers. Its most important customer groups appear to be:

Large biopharma companies: these customers need robust sample handling, validated processes, and scalable outsourced support across drug discovery and development.
Emerging biotech companies: smaller biotechs often want outsourced infrastructure because building storage, logistics, and sequencing capabilities in-house is capital intensive.
Academic and government research institutions: these customers use sequencing and sample management services but can be more exposed to funding cycles.
Contract research and development organizations: CROs, CDMOs, and other service organizations can use Azenta as an embedded workflow partner or equipment and consumables supplier.
Clinical, diagnostic, and biobanking organizations: these customers value sample traceability, storage reliability, and controlled handling, particularly for sensitive human specimens.

Azenta appears reasonably diversified by customer type within life sciences, though overall demand is still linked to research funding, biotech formation, and pharmaceutical development activity.

8. What Is the Sales Model of Azenta?

Azenta sells through a mix of direct enterprise sales, technical sales support, and digital ordering channels. The sales model differs by offering.

Sample Management Solutions: typically sold through direct sales and solution-oriented account management. Deals often involve workflow design, quality reviews, and integration into customer operations rather than simple catalog ordering.
Multiomics services: sold through a combination of field sales, inside sales, and digital ordering. Repeat ordering and customer convenience are especially important here.
Consumables and selected products: these may involve more transactional selling, though larger accounts still benefit from direct coverage.

This channel structure affects performance in several ways. Direct selling supports pricing and customer intimacy in complex sample management relationships. Digital ordering improves efficiency and repeat business in laboratory services. The model also creates consultant opportunities around salesforce design, key-account management, pricing, and cross-sell execution across the two segments.

9. In What Geographies Does Azenta Operate?

Azenta operates globally, with customers and facilities spread across North America, Europe, and Asia-Pacific. Its headquarters are in Burlington, Massachusetts, and public materials also point to meaningful operational presence in the United States, the United Kingdom, continental Europe, and parts of Asia, including China and Singapore.

From a practical operating perspective, Azenta’s geographic footprint matters in three ways:

Customer proximity: biopharma and biotech customers are concentrated in major research clusters, especially in the United States and Europe.
Laboratory and repository footprint: sample storage and omics services benefit from having regional infrastructure that can reduce transport time and support local service requirements.
Regulatory and logistics complexity: global movement of biological materials requires temperature control, documentation, and cross-border coordination, which raises the value of a multi-region operating network.

Azenta is globally active but not geographically indiscriminate. Its footprint is most valuable where research intensity and sample complexity are highest.

10. Who Are the Owners of Azenta?

Azenta is a publicly traded company with shares listed under the ticker AZTA. Based on public ownership disclosures through 2024, it does not appear to have a controlling shareholder. Its shareholder base is primarily institutional, with large asset managers such as The Vanguard Group, BlackRock, and State Street typically among the larger holders. Ownership information can change over time, so these names should be read as time-sensitive rather than permanent.

11. How Is Azenta Organized?

At the reporting level, Azenta is organized into two operating segments:

Sample Management Solutions
Multiomics

That reporting structure is also a useful way to understand the business economically. Sample Management Solutions contains the more infrastructure-like offerings: storage, repositories, logistics, consumables, and workflow support. Multiomics contains laboratory analysis services, including sequencing and related offerings.

At a practical level, Azenta also operates through a portfolio of acquired capabilities and brands, supported by central corporate functions such as finance, legal, information technology, human resources, and quality systems. This creates a hybrid model: segment-led customer offerings on the front end, with shared corporate capabilities and capital allocation on the back end.

12. How Does Azenta Operate?

Azenta’s day-to-day operation revolves around handling high-value samples without losing integrity, traceability, or turnaround speed.

How Sample Management Solutions works

Customers send samples or ask Azenta to manage them within outsourced repositories. Azenta receives, accessiones, labels, stores, and tracks those materials under specified temperature conditions. It then retrieves, sorts, aliquots, repackages, and ships samples as customers need them. Value is created through accuracy, uptime, temperature control, and chain-of-custody documentation. In this business, a mistake can destroy scientific value or create compliance risk, so operational discipline is central.

How Multiomics works

Customers submit samples for laboratory analysis. Azenta performs sample intake, quality checks, preparation, sequencing or related workflows, data processing, and result delivery. Here, turnaround time, data quality, laboratory throughput, and customer experience all matter. Utilization is especially important because underused labs can pressure margins.

Operational complexities

Azenta must manage a mix of physical logistics and information logistics. Biological materials require careful packaging, transport, and storage; data and metadata must remain accurate and linked to each sample; and global operations create regulatory and customs complexity. The combination of cold-chain operations, laboratory services, automation, and software is what makes the model harder to replicate than a simple testing service.

13. What Are the Growth Opportunities for Azenta?

The most credible growth opportunities for Azenta are those that build on existing workflow positions rather than radically changing the portfolio.

Deeper outsourcing by biopharma and biotech customers: as labs try to stay asset-light, more sample storage and handling can move to specialized external providers.
Cross-selling between segments: Azenta can try to win sequencing and analytical work from repository customers, and vice versa.
Cell and gene therapy, biologics, and other cold-chain-sensitive workflows: these areas reward documented handling and temperature control.
International expansion in research-intensive regions: additional density in Europe and Asia can improve customer proximity and service speed.
Higher-value omics mix: improving the revenue mix within Multiomics could support better margins if Azenta emphasizes differentiated services rather than pure commodity volume.
Tuck-in acquisitions: Azenta’s portfolio history and balance sheet suggest room for selected deals in adjacent tools, consumables, software, storage, or specialty services.

The main constraints are also clear: research funding cycles, biotech demand volatility, price competition in genomics, integration risk from acquisitions, and the need to keep utilization high in both repositories and labs.

14. What Is the History of Azenta?

Azenta traces its roots to 1978, when the company was founded as Brooks Automation. For much of its history, Brooks was primarily known for semiconductor automation and related industrial automation technologies rather than life sciences.

During the 2010s, the company increasingly built a life sciences platform through acquisitions and internal expansion. That shift brought in capabilities such as sample storage, repository services, cold-chain handling, and genomics. The transformation accelerated with major life sciences acquisitions including BioStorage Technologies and GENEWIZ.

The defining portfolio event came in 2022, when Brooks completed the sale of its semiconductor automation business to Thomas H. Lee Partners and rebranded as Azenta. That transaction turned the company into a focused life sciences tools and services business. Since then, Azenta’s history has been less about diversification and more about refining a pure-play model built around sample management and omics services.

15. What Are the Key Brands Owned by Azenta?

Brand matters at Azenta, but mainly as a trust and workflow signal rather than as a consumer marketing lever.

Azenta: the main corporate and enterprise brand. It represents the integrated life sciences platform, especially in sample management, storage, logistics, and infrastructure-like services.
GENEWIZ: one of Azenta’s most important customer-facing brands within Multiomics. It is closely associated with sequencing and related genomic services and has historically been strong in repeat, digitally enabled ordering.
4titude: a specialized labware and consumables brand that supports sample management workflows, particularly where automation compatibility matters.

Azenta’s brand architecture is therefore partly branded-house and partly portfolio-based. The Azenta name anchors the enterprise proposition, while GENEWIZ and certain product brands retain relevance where customer recognition is already strong.

16. How Does the Supply Chain of Azenta Function?

Azenta’s supply chain is important because the company is not just a laboratory services provider. It sits at the intersection of storage infrastructure, consumables, transportation, and lab operations.

Sourcing: key inputs likely include plastics and labware components, reagents, packaging materials, automation components, temperature-control equipment, and logistics services.
Manufacturing and assembly: consumables and certain workflow products may be manufactured internally or through specialized external partners, while automation systems depend on reliable component sourcing and assembly quality.
Warehousing and inventory: Azenta must hold inventory for consumables and operational materials while also managing capacity in repositories and labs.
Transportation: inbound and outbound movements matter, especially for temperature-sensitive samples and international shipments.
Service logistics: the final mile is not just delivery; it is documented custody and condition control.

What makes Azenta’s supply chain strategically important is that a logistics failure is not merely a cost problem. It can destroy sample value, break compliance, and damage customer trust. Reliability therefore matters as much as efficiency.

17. What Are the Key Assets of Azenta?

Azenta is not as asset-heavy as an airline or utility, but it does own and operate a meaningful set of specialized assets that matter to competition.

Biorepository and storage infrastructure: facilities and systems capable of storing samples across controlled temperature ranges.
Laboratory network: labs used for sequencing and related omics services.
Automation and handling systems: hardware and workflow tools that support retrieval, sorting, and sample management at scale.
Informatics and data systems: software, sample tracking, and data management tools that preserve chain of identity and chain of custody.
Installed customer relationships: not a balance-sheet asset, but strategically one of the most valuable assets because sample-management relationships tend to be sticky once embedded.

These assets matter because they create switching costs, require specialized know-how, and can produce operating leverage when utilization improves. They also make capital allocation important: adding capacity too early can dilute returns, but underinvesting can constrain growth.

18. What Is the Technology Strategy of Azenta?

Technology is central to Azenta in two different ways: as an internal operating backbone and as part of the customer value proposition.

Technology as an internal enabler

Azenta relies on automation, laboratory information systems, tracking software, and workflow integration to run repositories and labs accurately. Its heritage as Brooks Automation is relevant here; the company’s operating model still reflects an automation mindset, especially where precision and repeatability matter.

Technology as part of the customer offering

For customers, the technology value lies in visibility and control: sample tracking, inventory management, digital ordering, data delivery, and integration into research workflows. In sample management, the combination of physical storage and digital traceability is a major part of the product. In Multiomics, bioinformatics pipelines and user-friendly order-to-results workflows help differentiate the service.

Why it matters strategically

Azenta’s technology strategy is less about breakthrough platform invention and more about making complex scientific operations dependable, scalable, and easy to use. That is a sensible approach for a company competing on operational trust rather than on pure instrument innovation.

19. What Is the Finance Strategy of Azenta?

Azenta’s finance strategy has been shaped by the 2022 sale of its semiconductor automation business, which gave the company a more focused portfolio and substantial financial flexibility. Since then, the central finance questions have been how to deploy capital in a disciplined way and how to improve the earnings quality of the pure-play life sciences model.

Maintain strategic flexibility: a strong balance sheet gives Azenta room to invest in capacity, technology, and tuck-in acquisitions without depending heavily on leverage.
Improve segment profitability: especially in Multiomics, margin improvement and better cost absorption are financially important because the segment’s economics can be more volatile.
Allocate capital selectively: repositories, laboratories, and automation infrastructure can support growth, but only if utilization justifies the spending.
Balance reinvestment and shareholder returns: public companies in Azenta’s position often weigh organic investment, acquisitions, and repurchases against each other; the key strategic issue is not financial engineering but choosing the highest-return use of cash.

In short, finance strategy at Azenta is tightly linked to portfolio strategy. The goal is not simply to grow revenue, but to build a more resilient and higher-quality earnings base around specialized life sciences workflows.

20. What Major Acquisitions Has Azenta Made?

Acquisitions have played a major role in turning Azenta from an industrial automation company into a life sciences platform. Several deals stand out:

RTS Life Science (2011): helped expand Brooks into automated sample storage and related life sciences workflows.
BioStorage Technologies (2015): added outsourced sample repository services and strengthened biostorage capabilities.
GENEWIZ (2018): a major move into genomic services that later became a core part of Azenta’s Multiomics business.
4titude (2022): expanded the company’s portfolio in sample-management consumables and automation-compatible labware.

Just as important as the acquisitions was a major divestiture: in 2022, Brooks completed the sale of its semiconductor automation business for approximately $3 billion in cash and rebranded as Azenta. That transaction effectively reset the company’s strategic identity.

Overall, M&A has not just supplemented Azenta’s strategy; it has defined it. The company’s modern portfolio is largely the result of buying adjacent capabilities and then shedding the legacy business that no longer fit.

21. How Companies Like Azenta Leverage Independent Consultants through Umbrex

Azenta’s strategic agenda spans portfolio choices, laboratory operations, commercial execution, pricing, digital workflows, and selective M&A. Companies like Azenta often need targeted problem-solving in those areas without hiring a full large-firm consulting team. Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. That makes Umbrex relevant when a company like Azenta wants experienced consulting talent in strategy, operations, organization, marketing, sales, finance, technology, ERP, or AI on a focused basis.

Portfolio strategy review: assess the long-term role of Sample Management Solutions versus Multiomics and define where Azenta should concentrate capital and management attention.
Multiomics profitability program: redesign lab network economics, improve utilization, reduce turnaround bottlenecks, and sharpen service mix.
Cross-sell growth engine: build a commercial playbook to increase attachment rates between sample storage, cold-chain logistics, consumables, and omics services.
Pricing architecture: redesign pricing and discount governance for repository services, per-sample workflows, and sequencing orders.
Key-account segmentation: identify the highest-value biopharma, biotech, academic, and CRO accounts and tailor coverage models by customer type.
Global footprint optimization: evaluate where Azenta should add, consolidate, or specialize labs, repositories, and service hubs by region.
Procurement and supply-chain improvement: reduce cost and risk across reagents, plastics, packaging, freight, and automation components while protecting service quality.
M&A target screening and diligence: identify attractive tuck-in acquisitions in sample management, informatics, consumables, logistics, or specialty omics.
Post-merger integration: integrate acquired laboratory or sample-management businesses with clear synergy tracking and minimal customer disruption.
Digital and AI roadmap: prioritize customer portals, sample informatics, workflow automation, and analytics use cases that improve service reliability and productivity.